Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia

Martí‐Carvajal, Arturo J; Simancas‐Racines, Daniel; Cardona, Andrés Felipe

doi:10.1002/14651858.cd008562.pub2

Cited by 8 publications

(5 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Heparin use is not supported by evidence and must be avoided in such a complex situation. Two new candidates for the treatment of DIC are thrombomodulin and the older tranexamic acid but still lack evidence of effi cacy (47) (48) . Finally, patients with hemorrhage and jaundice should have additional and proper treatment with vitamin K. When facing such uncertainty, clinical trials with these drugs or new candidates should be urgently performed in patients with kala-azar and hemorrhage.…”

Section: Discussionmentioning

confidence: 99%

Predicting death from kala-azar: construction, development, and validation of a score set and accompanying software

Costa

Rocha

Chaves³

et al. 2016

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Predicting death from kala-azar: construction, development, and validation of a score set and accompanying software

Costa

Rocha

Chaves³

et al. 2016

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

“…Unlike heparin and protease inhibitors, rhs-TM is a very expensive drug. 28 The medical cost incurred during hospitalization did not dramatically increase with the frequency of use of rhs-TM in this study. However, the use of rhs-TM can undoubtedly increase the medical costs incurred during hospitalization.…”

Section: Discussionmentioning

confidence: 49%

Recent Change in Treatment of Disseminated Intravascular Coagulation in Japan

Murata

Okamoto

Mayumi

et al. 2015

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

This study investigated the time trends and hospital factors affecting the use of drugs for infectious disease-associated disseminated intravascular coagulation (DIC) based on a national administrative database. A total of 14 324 patients with infectious disease-associated DIC were referred to 1041 hospitals from 2010 to 2012 in Japan. Patients' data were collected from the administrative database to determine time trends and hospital factors affecting the use of drugs for DIC. Three study periods were established, namely, the fiscal years 2010 (n ¼ 3308), 2011 (n ¼ 5403), and 2012 (n ¼ 5613). The use of antithrombin, heparin, protease inhibitors, and recombinant human soluble thrombomodulin (rhs-TM) for DIC was evaluated. The frequency of use of antithrombin, heparin, and protease inhibitors decreased while that of rhs-TM significantly increased from 2010 to 2012 in Japan (25.1% in 2010, 43.1% in 2011, and 56.8% in 2012; P < .001, respectively). Logistic regression showed that the study period was associated with the use of rhs-TM in patients with DIC. The odds ratio (OR) for 2011 was 2.34 (95% confidence interval [CI], 2.12-2.58; P < .001) whereas that for 2012 was 4.34 (95% CI, 3.94-4.79; P < .001). A large hospital size was the most significant factor associated with the use of rhs-TM in patients with DIC (OR, 3.14; 95% CI, 2.68-3.66; P < .001). The use of rhs-TM has dramatically increased. A large hospital size was significantly associated with the increased use of rhs-TM in patients with DIC from 2010 to 2012 in Japan.

show abstract

“…Given that early death occurs mainly as a result of complications from coagulopathy (bleeding and thrombosis) 11,16 , which develops early and can progress rapidly, early consideration of the possibility of apl and the immediate initiation of treatment once apl is suspected (and before it is proven) is critical.…”

Section: Questionmentioning

confidence: 99%

A Canadian Consensus on the Management of Newly Diagnosed and Relapsed Acute Promyelocytic Leukemia in Adults

et al. 2014

View full text Add to dashboard Cite

The use of all-trans-retinoic acid (ATRA) and anthracyclines (with or without cytarabine) in the treatment of acute promyelocytic leukemia (APL) has dramatically changed the management and outcome of the disease over the past few decades. The addition of arsenic trioxide (ATO) in the relapsed setting—and, more recently, in reduced-chemotherapy or chemotherapy-free approaches in the first-line setting—continues to improve treatment outcomes by reducing some of the toxicities associated with anthracycline-based approaches. Despite those successes, a high rate of early death from complications of coagulopathy remains the primary cause of treatment failure before treatment begins. In addition to that pressing issue, clarity is needed about the use of ATO in the first-line setting and the role of hematopoietic stem-cell transplantation (HSCT) in the relapsed setting. The aim for the present consensus was to provide guidance to health care professionals about strategies to reduce the early death rate, information on the indications for HSCT and on the use of ATO in induction and consolidation in low-to-intermediate–risk and high-risk APL patients.

show abstract

Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia

Cited by 8 publications

References 68 publications

Predicting death from kala-azar: construction, development, and validation of a score set and accompanying software

Predicting death from kala-azar: construction, development, and validation of a score set and accompanying software

Recent Change in Treatment of Disseminated Intravascular Coagulation in Japan

A Canadian Consensus on the Management of Newly Diagnosed and Relapsed Acute Promyelocytic Leukemia in Adults

Contact Info

Product

Resources

About